NEW YORK, July 2 (newratings.com) - Analysts at Lazard Capital initiate coverage of Endologix Inc (
ELGX -
news) (ticker: ELGX) with a "buy" rating.
The target price is set to $6.
In a research note published this morning, the analysts mention that the advantages of the company's EVAR product have enabled it to gain market share. Endologix offers significant advantages to patients, physicians and payors, the analysts say. The company has registered significant revenue and gross margin growth in recent years, Lazard Capital adds.
© 2009 New Ratings
Send Article by Email
Send Article by IM
Blog This with Y! 360
Printable View
